Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen/UCB's romosozumab writes script for osteoporosis sequel

This article was originally published in Scrip

Executive Summary

Amgen and UCB's investigational sclerostin inhibitor, romosozumab, can produce increases in bone mineral density (BMD) significantly greater than those seen with the older osteoporosis treatments Fosamax (alendronate sodium) and Lilly's Forteo/Forsteo (teriparatide), exploratory analyses of Phase II data suggest. One commentator has suggested that as long as Phase III studies translate the early promise into antifracture efficacy and confirm long-term safety, romosozumab may represent "a sequel to the anabolic story" more than a decade after the introduction of teriparatide.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC023965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel